These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 10650901

  • 1. High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.
    Cascinu S, Bichisao E, Amadori D, Silingardi V, Giordani P, Sansoni E, Luppi G, Catalano V, Agostinelli R, Catalano G.
    Support Care Cancer; 2000 Jan; 8(1):65-7. PubMed ID: 10650901
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients.
    Geller RB, Gilmore CE, Dix SP, Lin LS, Topping DL, Davidson TG, Holland HK, Wingard JR.
    Am J Hematol; 1995 Nov; 50(3):167-72. PubMed ID: 7485077
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
    Cascinu S, Fedeli A, Fedeli SL, Catalano G.
    J Clin Oncol; 1993 Jan; 11(1):148-51. PubMed ID: 8418225
    [Abstract] [Full Text] [Related]

  • 5. [Management of chemotherapy induced diarrhea].
    Schultz M, Schölmerich J, Kullmann F.
    Z Gastroenterol; 2004 Jun; 42(6):527-38. PubMed ID: 15190449
    [Abstract] [Full Text] [Related]

  • 6. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
    Lenfers BH, Loeffler TM, Droege CM, Hausamen TU.
    Ann Oncol; 1999 Oct; 10(10):1251-3. PubMed ID: 10586346
    [Abstract] [Full Text] [Related]

  • 7. Management of acute cancer treatment-induced diarrhea.
    Stern J, Ippoliti C.
    Semin Oncol Nurs; 2003 Nov; 19(4 Suppl 3):11-6. PubMed ID: 14702928
    [Abstract] [Full Text] [Related]

  • 8. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
    Meropol NJ, Blumenson LE, Creaven PJ.
    Am J Clin Oncol; 1998 Apr; 21(2):135-8. PubMed ID: 9537197
    [Abstract] [Full Text] [Related]

  • 9. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Szelényi H, Hohenberger P, Lochs H, Haboubi N, Berdel WE, Thiel E, Kreuser ED.
    Oncology; 2000 May; 58(4):273-9. PubMed ID: 10838491
    [Abstract] [Full Text] [Related]

  • 10. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E.
    J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
    [Abstract] [Full Text] [Related]

  • 11. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
    Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R.
    Cancer Chemother Pharmacol; 1998 Aug; 42(4):336-40. PubMed ID: 9744780
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
    Gebbia V, Carreca I, Testa A, Valenza R, Curto G, Cannata G, Borsellino N, Latteri MA, Cipolla C, Florena M.
    Anticancer Drugs; 1993 Aug; 4(4):443-5. PubMed ID: 8400346
    [Abstract] [Full Text] [Related]

  • 13. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
    Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP.
    Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
    [Abstract] [Full Text] [Related]

  • 14. Loperamide and cardiac events: Is high-dose use still safe for chemotherapy-induced diarrhea?
    de Lemos ML, Guenter J, Kletas V.
    J Oncol Pharm Pract; 2018 Dec; 24(8):634-636. PubMed ID: 28714380
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD.
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [Abstract] [Full Text] [Related]

  • 16. Octreotide in the treatment of severe chemotherapy-induced diarrhea.
    Zidan J, Haim N, Beny A, Stein M, Gez E, Kuten A.
    Ann Oncol; 2001 Feb; 12(2):227-9. PubMed ID: 11300329
    [Abstract] [Full Text] [Related]

  • 17. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E, Cervantes A, Carrato A, Antón-Torres A, Massutí T, Fernández-Martos C, Díaz-Rubio E.
    J Infus Chemother; 1996 Feb; 6(3):118-22. PubMed ID: 9229321
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study.
    Cascinu S, Barni S, Labianca R, Del Ferro E, Rocchi MB, Ligi M, Pessi MA, Cazzaniga M, Zamparelli G, Ardizzoia A, Ugolini G, Ghiandoni G, Luporini G, Catalano G.
    Support Care Cancer; 1997 Jul; 5(4):314-7. PubMed ID: 9257428
    [Abstract] [Full Text] [Related]

  • 19. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.
    Cascinu S, Fedeli A, Fedeli SL, Catalano G.
    Eur J Cancer; 1992 Jul; 28(2-3):482-3. PubMed ID: 1591068
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G, Tucci A, Rinaldi A, Colarusso D, Pizza C, Reggiardo G, Manzione L.
    Oncology; 2004 Jul; 66(5):371-8. PubMed ID: 15331924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.